[Corticotropic action of a new, synthetic analogue of ACTH (ACTH1-17) in man after intravenous, intramuscular and intranasal administration (author's transl)].
Ala1-lys17-ACTH(1-17)-4-amino-n-butylamide (ACTH1-17), a synthetic analogue of ACTH with shortened amino acid sequence exerts a corticotropic action of at least 8 hours duration in healthy male subjects after either intravenous or intramuscular administration. After intranasal administration of the compound an increased production of cortisol was observed only for three hours. The prolonged action of this new analogue of ACTH following intramuscular administration suggests that it may be of value for therapeutic purposes.
D000281:Administration, Intranasal; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D006728:Hormones / Q000008:administration & dosage*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male
D006728:Hormones; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone
Die kortikotrope Wirkung eines neuen, synthetischen ACTH-Analogons (ACTH1-17) am Menschen nach intravenöser, intramuskulärer und intranasaler Verabreichung.